Non-Targeted Screening as a Trigger: When Ranking Says ‘Test’



Non-Targeted Screening as a Trigger: When Ranking Says ‘Test’

Published on 08/12/2025

Non-Targeted Screening as a Trigger: When Ranking Says ‘Test’

Introduction: Understanding Nitrosamine Risk Assessment

The pharmaceutical industry is continually challenged by potential impurities that can impact drug safety and efficacy. Among such impurities, nitrosamines have garnered significant attention due to their classified status as probable human carcinogens. Nitrosamine risk assessment is a critical component of pharmaceutical quality management that requires thorough investigation into potential sources of contamination. This article provides a comprehensive step-by-step guide on performing nitrosamine risk assessments, focusing specifically on non-targeted screening (NTS) as a trigger for further testing when risk rankings necessitate action.

Step 1: Establishing a Risk Assessment Framework

Effective nitrosamine risk assessment starts with the establishment of a robust framework that aligns with regulatory guidelines set forth by organizations such as the FDA and EMA. The following steps outline how to create such a framework:

  • Identify the Scope: Determine the scope of the risk assessment. This includes defining the product lines, active pharmaceutical ingredients (APIs), and relevant processes affected by nitrosamines.
  • Develop Risk Criteria: Establish criteria for evaluating risks associated with nitrosamines. This might include acceptable thresholds such as the NDMA limit and the application of ICH M7 guidelines.
  • Gather Data: Collect all relevant data on the supplier, their manufacturing processes, and any previous experience with nitrosamines, particularly using the NDSRI (Nitrosamine Drug Substance Risk Index).

Step 2: Conducting Supplier Qualification

Supplier qualification plays a vital role in risk management. A systematic approach should be adopted to ensure suppliers adhere to stringent standards to minimize the risk of nitrosamine contamination. Follow the steps below:

  • Supplier Evaluation: Assess suppliers not just against basic criteria but specifically for their capability to eliminate or minimize the introduction of nitrosamines. This may include reviewing their manufacturing processes, operational history, and chemistries involved.
  • Request Documentation: Gather relevant documentation including certificates of analysis, batch records, and any history of compliance failures related to nitrosamine contamination.
  • Perform On-Site Audits: Conduct on-site audits when possible to verify claims. This step allows for the identification of potential risks in material handling and processing, which could contribute to nitrosamine formation.

Step 3: Implementing Non-Targeted Screening (NTS)

Non-targeted screening is essential for detecting unexpected nitrosamine impurities that may not be covered in preliminary assessments. Here’s how to implement NTS effectively:

  • Select Analytical Methods: Choose appropriate analytical techniques for NTS. The LC-MS/MS method and GC-MS headspace analysis are popular choices, offering high sensitivity and specificity in detecting nitrosamines.
  • Establish Screening Protocols: Develop standardized protocols specifying sample preparation, instrument calibration, and analytical conditions to be consistent across batches and suppliers.
  • Interpretation of Results: After conducting NTS, analyze the data to determine the presence and levels of nitrosamines compared to the established risk criteria. Assess if the detected levels surpass the thresholds defined by NDSRI limits.

Step 4: Ranking Risks Based on NTS Outcomes

Once NTS outcomes are gathered, it is critical to rank the risks associated with nitrosamine impurities effectively. The process involves:

  • Develop a Scoring Matrix: Create a scoring matrix to categorize the risk from nitrosamine presence, considering factors such as the severity of the impurity, frequency of occurrence, and the volume of product exposure to the impurity.
  • Engage Stakeholders: Involve cross-functional teams in risk determination. Collaborate with clinical, regulatory, and quality teams to ensure comprehensive risk evaluations and consensus on the actions required based on the risk ranking.
  • Decision Making: Establish decision criteria whereby certain thresholds will trigger further investigation (e.g., testing, process review) or actions such as changing suppliers or enhancing process controls.

Step 5: Establishing Control Strategies

With risk rankings in hand, appropriate control strategies must be developed to mitigate any identified risks. Consider the following strategies:

  • Enhanced Monitoring: Increase the frequency of nitrosamine testing for products that exceed risk thresholds, ensuring continuous compliance with limits set forth by ICH M7.
  • Process Improvements: Implement process modifications that could reduce the formation of nitrosamines, including adjustments in raw material sourcing and manufacturing conditions.
  • Supplier Collaboration: Work closely with suppliers identified in the risk-ranking process to establish better practices to eliminate nitrosamines from their manufacturing processes.

Step 6: Documentation and Reporting

Thorough documentation is paramount in achieving a defensible position during regulatory inspections and audits. Ensure documentation includes:

  • Risk Assessment Records: Archive all risk assessment reports detailing methodology, data analysis, and stakeholder approvals.
  • Testing Protocols: Maintain records of NTS results, analytical testing protocols, and any decisions made as a result of these findings.
  • Action Plans: Document any corrective actions taken in response to findings to provide traceability and support in compliance verifications.

Step 7: Continuous Improvement and Trending Analysis

Finally, establish a system for continuous improvement and trending analysis to optimize nitrosamine risk assessment efforts:

  • Regularly Review Policies: Continuously revisit and refine your risk assessment frameworks and control strategies to adapt to new information and regulatory updates.
  • Data Trending: Use statistical tools to analyze nitrosamine testing data over time. This trend analysis can help identify patterns and ensure that risk levels remain manageable.
  • Training and Awareness: Regularly train staff on updated protocols and encourage a culture of quality where employees are vigilant about identifying potential sources of nitrosamines.

Conclusion: The Importance of a Dynamic Nitrosamine Risk Assessment Process

In an environment where regulatory scrutiny is ever-increasing, maintaining a rigorous nitrosamine risk assessment process is vital for all pharmaceutical companies operating under cGMP. By diligently following the steps outlined above, organizations can ensure that they are not only compliant with regulatory expectations but also safeguarding public health through proactive impurity management. Through proper documentation, risk evaluation, and supplier qualifications, companies can feel confident in their strategies to address nitrosamines and other potential impurities head-on.